AndexXa

Large-cap biopharma Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced a deal Tuesday to buy its small-cap peer Portola Pharmaceuticals Inc (NASDAQ: PTLA). The news comes after two M&A announcements Monday in the biotech space. The Alexion Deal Terms Alexion said it has...

The year is drawing to the close, and biotech stocks have had a fairly good run despite the market-wide downturn in October and Novmeber. New molecular moiety (NME) approvals thus far this year totaled 52, already beating the previous year's number of 46. NMEs are active moieties that...

Portola Pharmaceuticals Inc (NASDAQ: PTLA) shares reclaimed the $40 level for the first time since February after a positive FDA decision on a drug meant to reverse anticoagulation brought about by drugs such as Bayer AG (ADR) (OTC: BAYRY)'s rivaroxaban, and apixaban jointly developed by...

Portola Pharmaceuticals Inc (NASDAQ: PTLA) plunged Thursday after the release of its fourth-quarter results. The company reported a narrower-than-expected loss for Q4 and provided a corporate update. The Analyst Morgan Stanley analyst Matthew Harrison downgraded shares of Portola Pharma from...

Morgan Stanley’s Matthew Harrison believes regulatory updates regarding AndexXa and betrixaban were key drivers for Portola Pharmaceuticals Inc (NASDAQ: PTLA), which could offer clarity regarding approval timelines and restore investor confidence. Harrison maintains an Overweight rating on...